Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Sanofi India Ltd...

    Sanofi India Ltd denied early Supreme Court hearing

    Written by Geeta Sharma Sharma Published On 2016-08-01T13:33:02+05:30  |  Updated On 1 Aug 2016 1:33 PM IST
    Sanofi India Ltd denied early Supreme Court hearing

    New Delhi: French Drug maker Sanofi has been denied an early hearing by the Supreme Court in the Rs 1,058 crore Sanofi SA cross border deal involving Hyderabad-based Shantha Biotechnic’s (SBL) Indian assets.Similarities can be drawn between Vodaphone’s $ 2 billion tax dispute and Sanofi’s cross border deal involving Shantha Biotechnic’s Indian assets.


    Senior Counsel, Harsh Salve’s plea for an early hearing of the department appeal against the Andhra Pradesh High Court’s February 15, 2013 order, that ruled in favour of Sanofi Pasteur Holding SA has been set aside by the Supreme Court on Monday.


    Sanofi India Ltd is currently trading at Rs. 4532.25, down by Rs. 50.05 or 1.09% from its previous closing of Rs. 4582.3 on the BSE.


    The scrip opened at Rs. 4597.55 and has touched a high and low of Rs. 4625 and Rs. 4530 respectively. So far 2848(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 10553.04 crore.

    The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 4770 on 04-Jul-2016 and a 52 week low of Rs. 3676 on 24-Jul-2015. Last one week high and low of the scrip stood at Rs. 4650 and Rs. 4470 respectively.

    The promoters holding in the company stood at 60.4 % while Institutions and Non-Institutions held 29.4 % and 10.2 % respectively.The stock is currently trading above its 50 DMA.

    Andhra Pradesh High CourtBSENSESanofi denied early hearingSanofi India LtdSBLShantha BiotechnicsSupreme Court
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Geeta Sharma Sharma
    Geeta Sharma Sharma
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok